SIU 2017 Prostate Cancer

SIU 2017: Clinical Activity of Abiraterone Acetate in Docetaxel-Naïve and Docetaxel-Pretreated Asian Patients with Metastatic Castration Resistant Prostate Cancer

Lisbon, Portugal (UroToday.com) In this abstract, the authors assess the role of abiraterone acetate, a CYP-17A inhibitor, in chemotherapy-naïve and chemotherapy-treated patients with mCRPC. While this has been established in Level 1 evidence (COU-301 and COU-302 studies), those studies were completed with minimal inclusion of Asian patients. Knowing the disease process is different in this population, the authors assess its efficacy in these disease stages. However, they compare patients treated pre-chemo to those treated after docetaxol, likely in an effort to determine sequencing.

SIU 2017: The Comparison of Prognoses between Radiotherapy and Radical Prostatectomy in Patients with High Risk Localized or Locally Advanced Prostate Cancer Treated with Neoadjuvant Hormonal Therapy

Lisbon, Portugal (UroToday.com) Patients with high-risk prostate cancer (PSA >= 20, Gleason score >= 8, or cT2-4) are typically offered radical prostatectomy or EBRT + ADT (recommended for 2 years). However, there are no prospective studies comparing these treatment options.

SIU 2017: Salvage Extended Lymph Node Dissection in Patients with Low Volume Lymph Node Recurrence after Primary Local Treatment: Multicenter Experience

Lisbon, Portugal (UroToday.com) PSMA-PET Scan is becoming increasingly popular in the setting of biochemical recurrence after PCa definitive therapy (XRT or RP) for identification of low-volume metastatic disease. However, while better than conventional imaging, it is not perfect.

SIU 2017: PSMA Positivity in Metastatic Prostate Cancer: A Morphological Bias?

SIU 2017: Observation of Preliminary Clinical Effect and Analysis of Perioperative Complications of Radical Prostatectomy for Patients with Oligo-Metastatic Prostate Cancer

Lisbon, Portugal (UroToday.com) Radical prostatectomy in the setting of metastatic prostate cancer is gaining more attention in the recent past based4. on retrospective series, small institutional series and population level analysis demonstrating modest benefit – typically in delay to systemic therapy and improved local control. While there are ongoing large multinational clinical trials to answer this question, the data will take many years to acquire.

SIU 2017: Prospective Comparative Analysis of Oncologic and Functional Outcomes Between Focal Therapy and Robotic Radical Prostatectomy

Lisbon, Portugal (UroToday.com) Focal therapy for localized prostate cancer has had increasing recognition and acceptance. However, while short term outcomes appear adequate, long-term data is still pending. By reducing impact on functional quality of life in men with low-volume disease, they help address a patient population often stuck between active surveillance and radical treatment. The ideal patient is not yet clear though, nor is the appropriate follow-up and triggers for reintervention/radical therapy.

SIU 2017: Conditional Probability of Biochemical Recurrence-Free Survival and Cancer-Specific Mortality after Radical Prostatectomy at Long Term Follow-Up

Lisbon, Portugal (UroToday.com) When it comes to counseling patients, we are often struggling to provide patients with updated survival benefits as they move further out from initial intervention. While our initial survival data is well established, as patients are further removed from their treatment, their survival estimates change – often for the better.

Page 1 of 8

SIU 2017 Prostate Cancer

Stay Connected

Login